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http://www.biomedcentral.com/1471-5945/14/8RESEARCH ARTICLE Open AccessmiR-125b induces cellular senescence in
malignant melanoma
Anne Marie Nyholm1, Catharina M Lerche1, Valentina Manfé1, Edyta Biskup1, Peter Johansen2, Niels Morling2,
Birthe Mørk Thomsen3, Martin Glud1 and Robert Gniadecki1*Abstract
Background: Micro RNAs (miRs) have emerged as key regulators during oncogenesis. They have been found to
regulate cell proliferation, differentiation, and apoptosis. Mir-125b has been identified as an oncomir in various
forms of tumours, but we have previously proposed that miR-125b is a suppressor of lymph node metastasis in
cutaneous malignant melanoma. Our goal was therefore to further examine this theory.
Methods: We used in-situ-hybridization to visualise miR-125b expression in primary tumours and in lymph node
metastasis. Then using a miRVector plasmid containing a miR-125b-1 insert we transfected melanoma cell line
Mel-Juso and then investigated the effect of the presence of a stable overexpression of miR-125b on growth
by western blotting, flow cytometry and β-galactosidase staining. The tumourogenicity of the transfected cells
was tested using a murine model and the tumours were further examined with in-situ-hybridization.
Results: In primary human tumours and in lymph node metastases increased expression of miR-125b was found in
single, large tumour cells with abundant cytoplasm. A stable overexpression of miR-125b in human melanoma cell
line Mel-Juso resulted in a G0/G1 cell cycle block and emergence of large cells expressing senescence markers:
senescence-associated beta-galactosidase, p21, p27 and p53. Mel-Juso cells overexpressing miR-125b were
tumourigenic in mice, but the tumours exhibited higher level of cell senescence and decreased expression of
proliferation markers, cyclin D1 and Ki67 than the control tumours.
Conclusions: Our results confirm the theory that miR-125b functions as a tumour supressor in cutaneous malignant
melanoma by regulating cellular senescence, which is one of the central mechanisms protecting against the
development and progression of malignant melanoma.
Keywords: hsa-miR-125b, Melanoma, Senescence, In-situ-hybridization, Mel-JusoBackground
Replicative cellular senescence is the principal mechan-
ism limiting proliferation of normal human cells [1,2].
After approximately 40–60 cell divisions (the Hayflick
limit) the cells enter a senescence-associated, irreversible
mitotic arrest and exhibit characteristic features com-
prising flattened morphology with abundant cytoplasm
and biochemical markers such as senescence-associated
beta-galactosidase (SA-beta-gal), p53 and cell cycle In-
hibitors (p16, p21, p27) [3]. Telomere shortening is the* Correspondence: r.gniadecki@gmail.com
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reproduction in any medium, provided the orprimary mechanism of replicative senescence in normal
diploid cells [4].
It has recently been discovered that various forms of
DNA and cellular damage may cause premature cellular
senescence before achieving the Hayflick limit. Interest-
ingly, activation of oncogenes provides a potent senes-
cence signal (oncogene-induced-senescence, OIS) which
is considered to be an early protective mechanism against
development of cancer [3,5-7]. Increased SA-beta-gal stain-
ing is seen in a variety of pre-malignant conditions, such as
lung adenomas, congenital naevi, benign prostatic hyper-
plasia and premalignant prostatic intraepithelial neoplasia
supporting the role of OIS in early control of malignancy
[3,5,8,9]. It has also been observed that progression to the
invasive tumour stage is associated with a suppression ofl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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ism inhibiting cancer progression, since senescence-like
state can be induced in established tumours and can-
cer cell lines by a variety of mechanisms including
chemotherapeutic agents or radiation (therapy-induced
senescence, TIS) [11,12].
Cutaneous malignant melanoma (MM) is a common,
highly aggressive cancer derived from the melanocytes
in the skin. MM is an area of high medical need since
the metastasis occurs early despite a very low primary
tumour mass and metastatic disease is highly resistant to
chemotherapy and radiotherapy. MM cells are resistant
to apoptosis and the induction of cellular senescence
could be explored as a novel approach to therapy [13].
MicroRNAs (miRNA) are 21–25 nt non-coding RNA
molecules, which bind to the 3′UTR of mRNAs confer-
ring translational inhibition or degradation [14]. MiRNAs
have been found to regulate cell proliferation, differenti-
ation, and apoptosis [15-17] and they have also been im-
plicated in the regulation of senescence (miR-29, miR-30,
miR-34a, miR-34b, miR-34c, miR122 miR-203, miR-205
and miR-217) [18-23] mostly by interfering with either
the p53 pathway or the retinoblastoma RB1/E2F function.
By an extensive analysis and comparison of miRNA ex-
pression levels Kozubek et al. showed that it was pos-
sible to distinguish melanoma speciments from benign
neavi based on the miRNA signature [24]. This supports
the theory that miRNA level may influence the develop-
ment MM.
Two independent research groups have reported a
miRNA-dependent induction of senescence in MM cell
lines with a focus on miR-205/miR-203-E2F axis [23,25].
By comparing miR expression profiles in metastasiz-
ing and non-metastasizing MM we proposed that miR-
125b is implicated in the progression of human MM
[26]. MiR-125b expression is decreased in the primary
cutaneous MM producing sentinel node metastasis
comparing to the T-stage-matched non-metastasizing
tumours [26]. This has later been confirmed by other
groups [27,28]. Mir-125b is a known oncomir and has
been implicated in the pathogenesis of leukemias and
B-cell lymphomas, breast cancer, squamous cell car-
cinoma, urothelial carcinoma, prostate carcinoma and
colon cancer [29-35]. In MM it has been shown to be
related to the pigmentation level [27]. Kappelmann
et al. showed that treatment of MM cells with pre-
mir-125b resulted in a strong suppression of cellular
proliferation [28].
We have gathered preliminary evidence that miR-125b
may be involved in the regulation of senescence in MM
[36]. In this paper we show that upregulation of miR-125b
induces senescence and might constitute one of the pos-
sible mechanisms of the suppressive effect of miR-125b
in MM.Methods
Cell culture
Human MM cell line Mel-Juso (DSMZ, Braunschweig,
Germany) was grown in DMEM Glutamax (Invitrogen,
Carlsbad, CA) with 10% FBS (Life Technologies, LT) in
37°C and 5% CO2. Transfected Mel-Juso cells were cul-
tured in selection medium, which was the same medium
supplemented with 10-μg/mL blasticidin (Invitrogen).
Plasmid transfection
Mel-Juso cells were transfected with a miRVector plasmid
containing a miR-125b-1 [UCSC Genome Bioinformatics:
uc010rzr.1] [37] insert and a blasticidin resistance gene
(miRVec-125b) [38] or the control miRNA Vector plas-
mid with a blasticidin resistance gene but without any
insert (miRVec-control) (Source BioScience, LifeSciences,
Nottingham, UK) (map and sequence of miR-125b, see
Additional file 1: Figure S1). 300.000 cells were seeded out
24 h before transfection to reach a confluency of 70–
90%. 1 μg of the plasmid was mixed with 400 μl OPTI-
MEM (Invitrogen) and 5 μl Lipofectamine RNAiMax
(Invitrogen). The mixture was incubated at room tem-
perature (RT) for 20 min and added to freshly washed
Mel-Juso cells in 1600 μl culture medium for 24 h followed
by a 14-day-culture in the selection medium in 37°C/5%
CO2. miR-125b expression was confirmed using PCR in
each clone. Optimisation in the beginning of the study
showed that the transfection efficacy in Mel-Juso cells was
higher with Lipofectamine RNAiMax than any other trans-
fection reagents. Transfection procedure was done in four
replicates for each plasmid and each evaluated using PCR.
Flow cytometry
For the measurement of BrdU incorporation, Mel-Juso
cells transfected with miRVec-125b or the miRVec-control
were pulsed for 20 min with 10 μM BrdU, fixed in 70%
ethanol for at least 2 h, washed with phosphate-buffered
saline (PBS), incubated in 2 N HCl for 30 min, washed in
neutralizing buffer (0.2 M Na2B4O7, pH 8.5) and resus-
pended in dilution buffer (0.5% Tween 20 and 0.5% bovine
serum albumin in PBS) prior to the addition of anti-BrdU
mouse antibodies (Becton Dickinson, Franklin Lakes, NJ).
Goat anti-mouse antibodies labeled with Alexa-Fluor
488 (1:1000; Invitrogen, Carlsbad, CA) were applied as
secondary antibodies. DNA was stained with 0.0003%
(30–40 μl per samlpe) 7-amino-actinomycin D solution
(7AAD; Beckman Coulter, Brea, CA). Samples were ana-
lyzed by means of flow cytometry (Beckman-Coulter,
Fullerton, CA). BrdU-positive events (FL1) were plotted
versus cellular DNA content (FL3).
Tumour formation in mice
Mice experiments were performed in accordance with the
national law for the experiments on animals of 14 Jun
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dk/Forms/r0710.aspx?id=145380) and supervised by an
authorised researcher (CML). All mice work is ap-
proved by Dyreforsoegstilsynet (generel permit for our
laboratory work in mice, permit number 2012-15-2934-
00419). All surgery was performed under sodium pento-
barbital anesthesia, and every effort was made to minimize
suffering.
Six Male BALB/C nude mice (Taconic, Rye, Denmark),
7 weeks of age, were housed in separate boxes with free
access to water and standard laboratory food, in an animal
facility at a 12 h light/dark cycle and the temperature 23°-
24°C. Mice were acclimatized for one week before the
experiments. Subsequently they were anesthetized with
0.05 ml HypDorm given subcutaneously and 5 x 106
Mel-Juso cells transfected with miRVec-125b vector or
the control vector in 0.2 ml PBS were injected subcutane-
ously into the left or right flank, respectively. Tumours
with a diameter of at least 1 mm were mapped separately
for each animal and followed until these reached a diam-
eter of 12 mm or for a maximum time of 4 weeks. Ani-
mals were killed and tumours were weighed and cut into
three parts, which were fixed in RNA Later (for RNA iso-
lation), 4% formalin (for standard histology, immunohis-
tochemistry and in situ hybridization) or were frozen
at −80°C (for SA-beta-gal staining). Formalin fixed sam-
ples were embedded in paraffin and serial sections were
stained with hematoxylin and eosin, Ki-67 and cyclin D1,
according to standard histopathology protocols. The
quantification of Ki-67 and cyclin D1 expression was
done semiquantitatively in each tumour using the follow-
ing ordinal scale: grade 1 (0%-25% positive tumour cells),
grade 2 (26%-50% positive cells), grade 3 (51%-75% posi-
tive cells), grade 4 (76%-100% positive cells). Lungs and
liver were taken out and cut in to three parts each, which
were treated as the tumour samples and checked for dis-
tance metastases.
In situ hybridization (ISH) for miR-125b
Formalin-fixed and paraffin-embedded human tissue
samples from the archives of the Department of Pathology
(Rigshospitalet, Copenhagen, Denmark) were stage T1-T4
cutaneous MM and matched lymph node metastases
(14 males and 3 females; mean age 52 years, range 24
to 83 years); mean Breslow depth 1.53 mm (range 0.37
to 4.00 mm); 15 superficial spreading MM and 2 nodu-
lar MM. Mouse tumour samples were prepared as de-
scribed above. Paraffin sections (6 μm) were mounted
on SuperFrost®Plus slides (Dako, Glostrup, Denmark)
and air-dried for 1–2 h at RT. Sections were deparaffi-
nized in xylene and hydrated through decreasing etha-
nol concentrations into PBS. Proteinase-K treatment
15 μg/ml in PK-buffer (5 mM Tris–HCl, pH 7.4, 1 mM
EDTA, 1 mM NaCl) was performed at 37°C for 8 minin a volume of 300 μL in a Dako hybridizer (Dako).
Sections were washed twice in sterile PBS and immedi-
ately dehydrated through an increasing gradient of ethanol
solutions. Aliquots of 3 different Mercury LNA miRNA
Detection Probes; hsa-miR-125b, scrambled probe, and
U6 snRNA (Exiqon, Vedbaek, Denmark) were then dena-
tured by heating to 90°C for 4 min and diluted to 40 nM,
40 nM, and 1 nM, respectively, in a formamide-free ISH
buffer (Exiqon). 50 μL probe mixture was hybridized with
the tissue sections in the hybridizer at 55°C for 60 min.
The slides were placed at RT in 5× saline-sodium citrate
(SSC) (Invitrogen) and stringency washes were performed
for 5 min each at 55°C in 5× SSC (one wash), 1× SSC (two
washes) and 0.2× SSC (two washes). The sections were
then washed in PBS and blocked with DIG Wash and
Block Buffer Set (Roche, Mannheim, Germany). Alkaline
phosphatase (AP)-conjugated anti-DIG (Roche) was di-
luted 1:800 in the blocking solution and incubated for
60 min at RT. Slides were washed twice with PBS con-
taining 0.1% Tween-20. Ready to use tablets (Roche) of
4-nitro-blue tetrazolium chloride (NBT) and 5-brom-
4-chloro-3′-indolyl-phosphate (BCIP) substrate were
dissolved in aqueous 0.2 mM levamisole. Slides were
incubated for 120 min at 30°C to develop the dark-blue
NBT-formazan precipitate. Sections were washed twice for
5 min in KTBT buffer (50 mM Tris–HCl, 150 mM NaCl,
10 mM KCl), and then twice in water, dehydrated in the
ethanol gradient and mounted.
SA-beta-gal staining
Monolayers of Mel-Juso cells transfected with miRVec-
125b or the miRVec-control after a 24-h culture in
4-chamber glass (Nunc, Rochester, NY) or cryostat tissue
sections from mice mounted on SuperFrost®Plus slides
were washed twice in PBS and fixed in 0.5% glutaralde-
hyde (pH = 7.0) for 15 min at RT. The samples were
washed twice with 20 ml 1 mM MgCl2in PBS (pH = 6.0)
and stained with the SA-beta-gal staining solution
containing 1 mg/ml of 5-bromo-4-chloro-3-indolyl beta-
galactopyranocid, 4% dimethylformamide, 0.0012 mM po-
tassium ferrocyanide and 1 mM MgCl2 in PBS (pH = 6.0)
for 4 h (Mel-Juso) or overnight (melanocytes) at 37°C [3,5].
Percentage of positive cells was evaluated blindely by one
of the investigators (RG).
Western blotting
Cells were washed in PBS and lysed in the sample buffer
0.5 M Tris–HCl pH 6.8; 5% glycerol; 10% SDS; DTT
0.2 M) supplemented with protease inhibitor cocktail
(Roche). Equal amounts of protein were separated by a
4-8% and 12% Bis-Tris gel electrophoresis at 200 V
followed by electrophoretic transfer to a nitrocellulose
membrane (Bio-Rad Laboratories, Hercules, CA). Mem-
branes were blocked for 1 h at 4°C with Li-Cor blocking
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the primary antibodies against β-actin (mouse) (Sigma
Aldrich, St. Louis, MO), p16 (mouse) (BD Pharmingen,
San Diego, CA), p21 (mouse) (Dako), p27 (mouse) (Santa
Cruz Biotechnology, Santa Cruz, CA) or p53 (rabbit)
(Dako) overnight at 4°C. Subsequently, they were in-
cubated for 1 h with the appropriate secondary anti-
bodies labeled with 800IR dye (anti-rabbit) (Li-Cor),
Alexa Fluor 680 (anti-mouse or anti-rat) both from Mo-
lecular Probes (Invitrogen). Protein bands were detected
and quantified with the infrared Odyssey imaging System
(Li-Cor). Quantified intensities were adjusted to the rele-
vant actin intensity and control and sample was then
compaired.
Clonogenic assay
10.000 Mel-Juso cells transfected with miRVec-125b or
the miRVec-control were seeded in 10 cm petri dishes
containing 10 ml selection medium and cultured for 10–
14 days until the appearance of macroscopically visible
colonies. The plates were washed, fixed in paraformal-
dehyde for 24 h and stained with crystal violet 0.05%
(Sigma Aldrich) for 20 min before washing in water.
Plates were photographed (microscope Olympus IX
70 and camera Nikon D60) and colonies were counted
manually.
Cell viability and apoptosis assessment
1.500.000 Mel-Juso cells transfected with miRVec-125b
or the miRVec-control were seeded in 10 cm Petri dishes
containing 10 ml selection medium, the medium changed
after 24 h and all (floating and adherent) cells collected
after another 24 h. Unfixed cells were stained simultan-
eously with FITC-Annexin-V and PI, according to the
manufacturer’s protocol (Beckman-Coulter, Fullerton, CA)
and analyzed by means of flow cytometry (Beckman-
Coulter, Fullerton, CA) as described previously [39].
RNA isolation and real-time q-PCR (RT-qPCR)
Mel-Juso cells transfected with miRVec-125b or the
miRVec-control were collected and washed twice in PBS.
Murine tumour tissue samples were homogenized using
a TissueLyzer II (Qiagen, Valencia, CA, USA) and proc-
essed as previously described [40]. Small RNAs were
purified using the mirVana Isolation Kit (Ambion, Foster
City, CA) and the PureLink RNA Micro to Midi Kit
(Invitrogen) according to the manufacturer’s instructions.
The concentration of RNA was measured spectrophoto-
metrically using NanoDrop ND-1000 (Thermo Scientific,
Wilmington, DE), and RNA integrity was confirmed
with Agilent 2100 Bioanalyzer using Agilent Nano RNA
kit (Agilent Technologies, Santa Clara, CA). miR-125b
expression was measured in the samples containing
the same amount of RNA with quantitative qRT-PCRassay (TaqMan TM microRNA Reverse Transcription
kit-4366596, and TaqMan Universal PCR Master mix-
4324018, Applied Biosystems, Foster City, CA) and vali-
dated primer sets (Applied Biosystems) according to the
manufacturer’s instructions. MiR-191 was used as a refer-
ence for the normalization of qRT-PCR-data. The q-PCR
was performed in triplicates using a 7900HT Fast Real-
Time PCR System (Applied Biosystems).
Sequencing
DNA was extracted from transfected Mel-Juso cell lines
containing either miRVec-125b or miRVec-control using
QIAamp DNA mini-Kit (Qiagen) in accordance with the
manufacturer’s protocol. PCR was made with reagents
from Life Technologies as follows: Master mix (10%
Gene amp PCR buffer II, 2.5 mM MgCl2, 400 μM dNTP,
0.2 μM of each primer and 1U Ampli Taq gold) was
prepared and 7.2 μL was mixed with 16.8 μL of ddH2O
and 1 μL of 5 ng/μL DNA (template). PCR was setup on
an Eppendorf MasterCycler gradient cycler (Hamburg,
Germany) with the following program: 95°C 10 min, then
35 cycles of: 95°C 30 s, 62°C 30 s and 72°C 1.5 min; ended
with 72°C 10 min and 4°C hold. The PCR product was
visually inspected on a 2.2% agarose gel on the Flashgel
system (Lonza, Basel, Switzerland). The remaining PCR
product was purified on Qiaquick columns (Qiagen) ac-
cording to manufacturer’s specifications and eluted in
50 μL buffer. Four μL of purified PCR product were used
as template in the sequencing reaction.
Sequencing was performed in duplicates with the Big-
Dye V.1.1 cycling sequencing kit (Life Technologies)
Samples consisted of 4 μL of Ready reaction mix, 2 μL
of BigDye buffer, 3.2 pmol of primer (forward-GCGTTT
AAACTTAAGCTTGGTACCGAGC, reverse-CATTCC
CCCCTTTTTCTGGAGAC), 4 μL of template and 20 μL
of ddH2O. Reactions were performed with forward and
reverse primers in duplicate with the following pro-
gram: 96°C 1 min, then 25 cycles of: 96°C 10s, 50°C
5 s and 60°C 4 min, ending with 4°C hold. PCR prod-
ucts were purified with Centrisep columns (Princeton
Separations, Adelphia, NJ) according to the manufac-
turer’s recommendations. Two μL of purified sequen-
cing product were mixed with 8 μL of HiDi formamide
and run on an ABI3130xl DNA Sequencer (Life Tech-
nologies) with the following specifications: Array 36 cm,
polymer POP4, injection voltage 3 kV, injection time
7 s, run voltage 15 kV and run time 1700 sec. One of
the reverse duplicates was removed due to low quality.
Results were analyzed and assembled with Sequencher
v.5 (Gene Codes Corporation, Ann Arbor, MI, USA).
Differences in the chromatograms were visually inspected.
Low quality regions resulting in differences were removed.
Sequence ends had to be cropped due to low reaction
quality.
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All numeric results are given as mean ± SD unless stated
otherwise. t-test was used for intergroup comparison. P
< 0.05 was considered significant.
Results
miR-125b is expressed in human primary cutaneous MM
and lymph node metastases
We have previously shown by miRNA array approach that
miR-125b is expressed in primary cutaneous MM [26,41].
By comparing metastasizing and non-metastasizing stage
T2 cutaneous MM we detected an overall decrease in
miR-125b expression in metastasizing tumours [26]. Here
we employed ISH to further define the expression pattern
of miR-125b in MM. As shown in Figure 1 miR-125b is
expressed in MM cells both in the primary tumours and
in the sentinel node metastases. The staining of miR-
125b seems to be located predominantly to the nuclei.
We noted that the expression was not homogenous and
some cells characterized by large size and abundant cyto-
plasm expressed higher amounts of miR-125b than other
cells (arrows in Figure 1A,B). These larger cells could
represent a more malignant, highly atypical tumour cell
population, but could also comprise the population of
cells undergoing spontaneous cellular senescence. Since
SA-beta-gal staining is not possible on paraffin-embedded
material and fresh samples from primary cutaneous MM
are not available due to ethical considerations, we de-
cided to examine the potential functional involvement
of miR-125b in MM cell proliferation and senescence
in vitro.Figure 1 Expression of miR-125b in primary cutaneous malignant me
cutaneous MM (stage T2; A, C) and a sentinel node with micrometastases (
control, scrambled probe (C). Arrows show the cells with prominent stainin
B x40, C x20, D x20.miR-125b inhibits proliferation and induces senescence in
human melanoma line Mel-Juso
Mel-Juso cell line is established from the primary tumour
of a 58-year-old woman with MM in 1977. This line has
wildtype BRAF, is poorly differentiated [42] and exhibits
intermediate invasiveness [43]. Transfection with miRVec-
125b resulted in an 8.0 ± 1.13-fold upregulation of
miR-125b by RT-qPCR compared to the miRVec-control
transfected cells. After the experiments were completed,
the miR-125b insert was sequenced to confirm that no mu-
tation had occurred in the miR-125b sequence of the insert
throughout the experimental period. For full insert consen-
sus sequence, see Additional file 1: Figure S2.
As shown in Figure 2A,B and E the miRVec-125b trans-
fected cells formed smaller and fewer colonies than
the control cells (930 ± 105.2, n = 4 replicates vs. 1207.5 ±
218.8, n = 4 replicates, p-value 0.011). The miRVec-125b
transfected cells showed a G0/G1 cell cycle arrest, demon-
strated in Figure 2 (F, G) by a significantly increased pro-
portion of G0/G1 cells (p < 0.05) and a significant decrease
in BrdU incorporation (p < 0.05).
Microscopic examination of the colonies (Figure 2C,D)
revealed that the miRVec-125b-transfected cells were en-
larged, flattened, and had abundant cytoplasm, consistent
with cellular senescence, in contrast with the normal
spindle-shaped cell morphology in the control group.
SA-beta-gal staining showed increased expression of
SA-beta-gal in estimated 60-70% of the miRVec-125b
transfected compared to estimated 5-10% of the control
cells (Figure 3A,B). Western blot analysis of the miRVec-
125b cells showed an up regulation of the expectedlanoma and lymph node metastases shown with ISH. Primary
B) were hybridized with the probe for miR-125b (A, B) or with the
g for miR-125b. (D) U6 probe (positive control). Magnification: A x60,
Figure 2 miR-125b inhibits the proliferation rate in cell line Mel-Juso. Transfected cells with miRVec-125b vector (B, D) or miRVec-control
plasmid (A, C). Colony formation (A, B), morphology of the colonies (C, D). (E) Quantification of colonies from the colony formation assay. * p = 0,011.
(F): Cell cycle analysis. The percentages of cells in G0/G1, S and G2/M phases are plotted for each group. ** p = 0,044, *** p = 0,01 (G) Cell proliferation
measured by BrdU incorporation **** p = 0.039.
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control. p16 was not expressed in the Mel-Juso cell line.
(Figure 3C).
To evaluate whether apoptosis was responsible for the
apparent lesser growth observed in the colony forming
assay we compared the proportions of annexin-positive
cells in the miRVec-125b transfected cells with the
controls. We found no evidence of apoptosis in either
group (95.5% ±0.7% annexin-negative, viable cells in the
miRVec-125b transfected cell line versus 94.7% ±1.2% in
the control; p = 0.46).
miR-125b expression in Mel-Juso cells induces senescence
and reduces proliferation in a murine tumour model
To further investigate the significance of miR-125b in
the regulation of MM growth we established an in vivo
model of tumour formation from Mel-Juso cells injected
subcutaneously into immunodeficient, nude BALB/c mice.In this model the Mel-Juso cells formed subcutaneous tu-
mours within a time span of 4 weeks, but did not produce
distant metastases (confirmed by macroscopic and histo-
logical examination of lung and liver tissue). ISH revealed
considerable expression of miR-125b in the tumours ori-
ginating from the miRVec-125b vector-transfected cells, in
contrast to a negligible expression in the tumours emer-
ging from the miRVec-control cells. The tumours were
very homogeny in their appearances which was consistent
with the fact that they were developed from a clone rather
than the normal progression from normal tissue to tumour
with the following heterogeneity otherwise known from
Melanoma tumours [44,45]. The stability of miR-125b
overexpression was confirmed by RT-q-PCR quantification
of miR-125b in the tumour tissue showing an 11.6 ± 6.0
fold increased expression in the miRVec-125b transfected
tumours. As could be expected from the in vitro experi-
ment, SA-beta-gal staining revealed a focal increase in the
Figure 3 miR-125b induces senescence in melanoma cell line Mel-J uso. SA-beta-gal staining for senescence stained in the miRVec-control
(A) and miRVec-125b (B) cells. (C) Western blot of senescence markers p16, p21, p27 and p53 and complimentary actin bands.
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originating from miRVec-125b -transfected cells. This was
paralleled by the marked decrease in the expression of pro-
liferation markers Ki67 and cyclin D1 (Figure 4). However,
we did not detect any difference in weight between the tu-
mours originating from miRVec-125b -transfected cells
and the control, miRVec-control transfected cells (mean
weight miR-125b: 0.021 g ± 0.003, control: 0.023 g ± 0.004).
Discussion
This study documented that stable, ectopic expression of
miR-125b induced cellular senescence in a MM cell line
Mel-Juso, both in vitro and in a xenotransplantation
model in mice in vivo. The results were surprising, since
miR-125b is generally considered to be an oncogene and
in a transgenic mouse model miR-125b overexpression
causes myeloid leukemia and B-cell malignancies [46,47].
However, our and other’s preliminary evidence sug-
gested that miR-125b has an anticancer effect in MM
[26,28,36,41] and its decreased expression correlated with
the metastatic potential of primary cutaneous MM. In
the present study we substantiated this hypothesis using
a model of stably transfected Mel-Juso cell line with the
miRVec-125b vector previously developed by Voorhoeve
et al. [38]. We were able to demonstrate an increase in
senescence markers (SA-beta-gal, p27, p21, p53) and de-
creased proliferation with a G0/G1 arrest in miRVec-
125b-transfected cells as compared with the control.miRVec-125b -transfected cells were tumourigenic in vivo,
but the tumours showed an increased rate of senescence
and decreased amount of proliferating cells, as measured
by Ki67 and cyclin D1 staining. Together with the results
of ISH showing that miR-125b is expressed in primary hu-
man MM and lymph node metastases, the data indicate
that miR-125b is implicated in the regulation of senescence
in human MM.
The mechanism by which miR-125b overexpression
promotes cellular senescence is unknown. MiR-125b
may negatively regulate the p53 tumour suppressor gene
and Bak1 [48] but such a downregulation has not been
seen in Mel-Juso cells in our experiments (data not
shown). Other known targets are BMF and Lin28a [49]
but they are unlikely to be involved in cellular senes-
cence in MM. In general, the functional role of miR-
125b seems to be cell specific, since in some types of
cancer (e.g. urothelial carcinoma) this miR seems to acts
as a tumour suppressor [34].
MiR-dependent induction of cellular senescence in
MM has recently and independently been demonstrated
by other researchers for miR-203 and miR-205 in cuta-
neous MM and for miR-34a in uveal MM [23,25,50]. A
common biochemical pathway in these cases seems to
be mediated by E2F and downregulation of Akt. This is
an unlikely mechanism in the case of miR-125b since
the screening for the effect of miR-125b overexpression
on Akt, Stat, mTOR did not show any changes in the
Figure 4 Reduced mitotic activity and increased senescence in tumours emerging from miRVec-125b transfected Mel-Juso cells shown
by (A) ISH with miR-125b (In situ miR-125b), SA-beta-galactosidase staining (X-gal), Ki67 and Cyclin D. The different stainings were not
made in paralelle. (B) Quantification of Ki67 and cyclin D expression in murine tumours by visual grading of the proportion of positive cells. In
one case the control and experimental tumours were too small for microscopic analysis and therefore the graph shows data for 5 tumours.
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proteins are not expressed in Mel-Juso cells (data not
shown).
In this study we used ISH to evaluate the miR-125b
expression locally in the tissue. We observed that the
ISH on human tissue samples showed a strong nucleic
concentration of miR-125b. This has been surprising
since the conventional theory requires the cytoplasmic
presence of miRNA for its proper function [51-53].
However, the studies on the compartmentalization of
miR-125b have been done with cell lines and not tissue
samples, like in our study. On the other hand, our ISH
staining on the murine tumours showed a more pro-
nounced cytoplasmic staining. One explanation of this
could be that the miR-125b distribution in the cell is dif-
ferent between cells from a cultivated cell line and cells
from tissue samples. Kobuzek et al. [24] showed that the
miR-125b signal in MM is different in tissue and cell lines.
Another explanation could be that the specific distribution
varies from tissue to tissue. This is supported by the fact
that ISH staining for miR-125b on other tissues have
showed that in some tissues there is a clear staining of the
nuclei [54-56] while in others the staining is mainly cyto-
plasmatic [57,58]. This will have to be validated in further
studies. It is finally possible, that nuclear miR-125b have a
distinct biological role, as previously suggested for other
miRNA species.
Another limitation of this study is that the functional
role of miR-125b has only been investigated in Mel-Juso
cells and it remains to be seen whether the same is valid
for other MM cell lines and primary melanocytes. These
experiments were attempted but failed due to massive
apoptotic response caused by miRVec-125b plasmid. It
is known that Mel-Juso cells are very resistant to apop-
tosis, which enabled us to achieve a stable miR-125b
overexpression. Second, we focused primarily on the ef-
fect of the sustained overexpression of miR-125b in MM
cells. The use of inducible miR-125b vectors will be
helpful to elucidate the effect of acute changes in miR-
125b levels.
Conclusion
Our results confirm the theory that miR-125b function
as a tumour supressor in cutaneous malignant melan-
oma by regulating cellular senescence, which is one of
the central mechanisms protecting against the develop-
ment and progression of malignant melanoma.
In view of the recent developments in the use of
miRNA mimics and inhibitors for therapy, it is conceiv-
able that miR-125b would be utilized for the treatment
of MM by inducing senescence of cancer cells. However,
as exemplified by our murine MM model, miR-125b in-
duces senescence focally in the tumours and the effect
on tumour mass is negligible. It is known that miRNAsact primarily as switches and amplifiers of the cellular
signaling pathways and their physiological effect is rarely
very strong [21]. It is therefore our goal for future research
to identify which signaling pathways of therapeutic rele-
vance are targeted by miR-125b and devise strategies by
which mir-125b overexpression may amplify the effect of
anticancer drug.
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